Prognostic value of IL-6 in localized prostatic cancer

Anticancer Res. 2010 Oct;30(10):4369-72.

Abstract

Aim: The usefulness of interleukin 6 (IL-6) and its soluble receptor IL-6sR in the prediction of the biochemical recurrence was evaluated in patients with prostate cancer treated with radical prostatectomy.

Patients and methods: IL-6 and sIL-6R serum levels were measured in 96 patients with prostate cancer.

Results: Using the log-rank test, it was evident that patients with preoperative serum levels of IL-6 higher than 1.2 pg/ml had a significantly increased probability of biochemical recurrence (p=0.031). We also observed that the Gleason score was associated with the risk of progression (p=0.033), but no relation was observed with TNM classification, PSA, % free PSA or sIL-6R. In a multivariate analysis, only IL-6 serum levels remained as a predictor of biochemical recurrence (p=0.040).

Conclusion: The results presented here demonstrated the usefulness of IL-6 in predicting the biochemical progression of prostate cancer, pointing towards an association between inflammation and the aggressiveness of the tumor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biomarkers, Tumor / blood*
  • Humans
  • Inflammation / blood
  • Inflammation / pathology
  • Interleukin-6 / blood*
  • Male
  • Middle Aged
  • Prostatectomy
  • Prostatic Neoplasms / blood*
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / surgery
  • Receptors, Interleukin-6 / metabolism

Substances

  • Biomarkers, Tumor
  • Interleukin-6
  • Receptors, Interleukin-6